研究抗体および試薬市場 : 2027年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年7月

研究抗体および試薬市場 : 製品(抗体(タイプ、フォーム、ソース、研究領域)、試薬)、テクノロジー(ウエスタンブロット、フローサイトメトリー、ELISA)、用途(プロテオミクス、ゲノミクス)、エンドユーザー(製薬、バイオテクノロジー、CRO)- 2027年までの世界予測
Research Antibodies & Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western blot, Flow Cytometry, ELISA), Application (Proteomics, Genomics), End User (Pharma, Biotech, CROs) – Global forecast to 2027

ページ数 276
図表数 290
種別 英文調査報告書
価格

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

The research antibodies and reagents market is projected to reach USD 16.1 billion by 2027 from USD 11.6 billion in 2022, at a CAGR of 6.7% during the forecast period. The research antibodies and reagents market evolved owing to factors such as increasing proteomics and genomics research, growing demand for antibodies for research reproducibility, and increasing R&D expenditure in the life sciences industry.

Driven by the increasing demand for personalized medicine and structure-based drug design. It is expected that the global research antibodies and reagentsmarket will witness significant growth in the coming years.

On the basis ofproduct, the reagentssegment holds the highest market share during the forecast period.
On the basis of product, the research antibodies and reagents market are segmented into reagent and antibodies. In 2021the reagent segment accounted for the larger market share. Factors such as increasing applications of biosciences and biotechnology within the healthcare and pharmaceutical fields is driving the market.

On the basis oftechnology, theflow cytometrysegmentis expected to register the highest CAGR during the forecast period.
On the basis of technology, the research antibodies and reagents market is segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. During the forecast period the flow cytometry segment is expected to witness the highest growth. Factors such as advantages of this technique, its ability to perform simultaneous multi-parameter analysis on single cells within a heterogeneous mixture, offering high throughput along with technological innovations in flow cytometry and increasingoncology research, are driving the growth of this segment.

On the basis ofapplication, the proteomicsholds the highest market share during the forecast period.
On the basis of application, the research antibodies and reagents market is segmented into proteomics, drug development and Genomics. In 2021, Proteomics held the largest share of the global research antibodies and reagents market. Factors such as increasing efficiency maps drug-protein and protein-protein interactions. Additionally, proteomic technologies have minimized the cost, time, and resource requirements for chemical synthesis and biological testing of drugs and are highly efficient. Such factors are driving the market.

On the basis of enduser, the pharmaceutical & biotechnology holds the highest market share during the forecast period.
The research antibodies and reagents market is divided into the pharmaceutical & biotechnology companies, academic & research institutions and Contract Research Organizations. In 2021the pharmaceutical & biotechnology companies held the largest share of the global research antibodies and reagents end-user market. Factors such as growing use of research antibodies in drug development for the identification and quantification of biomarkers and other techniques are driving the market.

By Region, The Asia Pacific region is expected to register the highest CAGR during the forecast period.

During the forecast period (2022 to 2027), the Asia Pacific research antibodies and reagents market is expected to grow at the highest CAGR. Factors such as increasing research in proteomics and genomics and growing research funding, investments by pharmaceutical and biotechnology companies, and growing awareness in the region are driving the market in the region.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45% and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, AsiaPacific–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the research antibodies and reagentsmarket

The key players operating in the research antibodies and reagents systems includeThermo Fisher Scientific, Inc. US), Merck KGaA (Germany), Abcam plc. (UK), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), Danaher Corporation (US), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), GenScript (China), and BioLegend (US).

Research Coverage:

The report analyzes the research antibodies and reagent marketand aims at estimating the market size and future growth potential of this market based on various segments such as product, distribution channel, andregion. The report also includes aproduct portfolio matrix of various research antibodies and reagents productsavailable in the market. The report also providesa competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.
Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would helpthem, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies tostrengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global research antibodies and reagentmarket. The report analyzes this marketby product and distribution channel.
• Product Enhancement/Innovation: Detailed insights on upcoming trends and productlaunches in the globalresearch antibodies and reagentmarket.
• Market Development: Comprehensive information on the lucrative emerging markets by product and distribution channel
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in theglobal research antibodies and reagent market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in theglobal research antibodies and reagent market.


目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 34)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKETS COVERED
FIGURE 1 GLOBAL RESEARCH ANTIBODIES AND REAGENTS MARKET
FIGURE 2 RESEARCH ANTIBODIES AND REAGENTS MARKET: GEOGRAPHIC SCOPE
1.2.3 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 STAKEHOLDERS
1.5 LIMITATIONS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 38)
2.1 RESEARCH APPROACH
FIGURE 3 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
FIGURE 4 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Breakdown of primaries
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 7 MARKET SIZING FROM COMPANY REVENUE
FIGURE 8 MARKET ANALYSIS APPROACH
FIGURE 9 TOP-DOWN APPROACH
2.3 DATA TRIANGULATION APPROACH
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. – 48)
FIGURE 11 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 12 RESEARCH ANTIBODIES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 13 RESEARCH REAGENTS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 14 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 15 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 16 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 17 GEOGRAPHIC ANALYSIS: RESEARCH ANTIBODIES AND REAGENTS MARKET

4 PREMIUM INSIGHTS (Page No. – 53)
4.1 RESEARCH ANTIBODIES AND REAGENTS: MARKET OVERVIEW
FIGURE 18 INCREASING R&D EXPENDITURE IN THE LIFE SCIENCE INDUSTRY TO DRIVE MARKET GROWTH
4.2 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION
FIGURE 19 PROTEOMICS ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC RESEARCH ANTIBODIES AND REAGENTS MARKET IN 2021
4.3 RESEARCH ANTIBODIES AND REAGENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 CHINA SHOWS THE HIGHEST REVENUE GROWTH OPPORTUNITIES DURING THE FORECAST PERIOD
4.4 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION
FIGURE 21 NORTH AMERICA WILL CONTINUE TO DOMINATE THE RESEARCH ANTIBODIES AND REAGENTS MARKET UNTIL 2027
4.5 RESEARCH ANTIBODIES AND REAGENTS MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 22 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE IN THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 57)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 23 RESEARCH ANTIBODIES AND REAGENTS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing research activity and funding for R&D
5.2.1.2 Growing industry-academia collaboration
TABLE 1 KEY MARKET DRIVERS: IMPACT ANALYSIS
5.2.2 RESTRAINTS
5.2.2.1 Quality concerns and a lack of reproducible results
TABLE 2 KEY MARKET RESTRAINTS: IMPACT ANALYSIS
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Personalized medicine and protein therapeutics
5.2.3.3 Growth in stem cell and neurobiology research
5.2.3.4 Increasing focus on biomarker discovery
5.2.3.5 Rising interest in outsourcing
TABLE 3 KEY MARKET OPPORTUNITIES: IMPACT ANALYSIS
5.2.4 CHALLENGES
5.2.4.1 Cost and time-intensive antibody development processes
5.2.4.2 Pricing pressure faced by prominent market players
TABLE 4 KEY MARKET CHALLENGES: IMPACT ANALYSIS
5.3 INDUSTRY TRENDS
5.3.1 INCREASING RESEARCH ON THERAPEUTIC ANTIBODIES
5.3.2 RECOMBINANT ANTIBODIES SUPPORTING THE SMOOTH TRANSITION FROM IN VITRO TO IN VIVO
5.3.3 GROWING CONSOLIDATION OF THE LIFE SCIENCES MARKET FOR ANTIBODIES AND REAGENTS
TABLE 5 MAJOR ACQUISITIONS IN THE RESEARCH ANTIBODIES AND REAGENTS MARKET
5.4 STAKEHOLDER ANALYSIS
FIGURE 24 RESEARCH ANTIBODIES AND REAGENTS MARKETS: STAKEHOLDER ANALYSIS (2021)
5.5 STRATEGIC BENCHMARKING
TABLE 6 PRODUCT PORTFOLIO ANALYSIS
5.6 IMPACT OF COVID-19 ON THE RESEARCH ANTIBODIES AND REAGENTS MARKET
5.7 SUPPLY CHAIN ANALYSIS
FIGURE 25 RESEARCH ANTIBODIES AND REAGENTS MARKET: SUPPLY CHAIN ANALYSIS
5.8 TECHNOLOGY ANALYSIS
5.9 REGULATORY ANALYSIS
5.10 PORTER’S FIVE FORCES
TABLE 7 RESEARCH ANTIBODIES AND REAGENTS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.10.1 THREAT OF NEW ENTRANTS
5.10.2 THREAT OF SUBSTITUTES
5.10.3 BARGAINING POWER OF SUPPLIERS
5.10.4 BARGAINING POWER OF BUYERS
5.10.5 DEGREE OF COMPETITION
5.11 PRICING ANALYSIS
TABLE 8 SELLING PRICE OF HPAPI PRODUCTS BY TOP PLAYERS

6 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT (Page No. – 75)
6.1 INTRODUCTION
TABLE 9 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
6.2 REAGENTS
TABLE 10 REAGENTS, BY TYPE
TABLE 11 RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 12 RESEARCH REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.1 MEDIA & SERA
6.2.1.1 Media & sera hold the largest share of the reagents market
TABLE 13 RESEARCH REAGENTS MARKET FOR MEDIA & SERA, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.2 STAINS & DYES
6.2.2.1 The growth of the life sciences industry is driving the demand and use of stains & dyes
TABLE 14 RESEARCH REAGENTS MARKET FOR STAINS & DYES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.3 FIXATIVES
6.2.3.1 Fixative agents are needed to preserve the morphology and antigenicity of target molecules
TABLE 15 RESEARCH REAGENTS MARKET FOR FIXATIVES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.4 BUFFERS
6.2.4.1 Wide use in drug development will drive the market for buffers
TABLE 16 RESEARCH REAGENTS MARKET FOR BUFFERS, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.5 SOLVENTS
6.2.5.1 Organic solvents see wide use in pharmaceutical processes and assays like IHC
TABLE 17 RESEARCH REAGENTS MARKET FOR SOLVENTS, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.6 ENZYMES
6.2.6.1 An increase in proteomic and genomic research activity will ensure the demand for enzymes
TABLE 18 RESEARCH REAGENTS MARKET FOR ENZYMES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.7 PROBES
6.2.7.1 The versatility, sensitivity, and quantitative capabilities of probes have ensured their use in research
TABLE 19 RESEARCH REAGENTS MARKET FOR PROBES, BY COUNTRY, 2020–2027 (USD MILLION)
6.2.8 OTHER REAGENTS
TABLE 20 OTHER RESEARCH REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 ANTIBODIES
TABLE 21 RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.1 ANTIBODIES, BY TYPE
TABLE 22 ANTIBODIES, BY TYPE
TABLE 23 RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.3.1.1 Primary antibodies
6.3.1.1.1 Rising R&D activity and expenditure driving the demand for accurate and reliable antibodies
TABLE 24 PRIMARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.1.2 Secondary antibodies
6.3.1.2.1 Versatility and low cost of production have ensured stable growth in the market for secondary antibodies
TABLE 25 SECONDARY RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2 ANTIBODIES, BY FORM
TABLE 26 ANTIBODIES, BY FORM
TABLE 27 RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
6.3.2.1 Monoclonal antibodies
6.3.2.1.1 Monoclonal antibodies are among the most common tools in biomedical science
TABLE 28 MONOCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2.2 Polyclonal antibodies
6.3.2.2.1 Thermo Fisher Scientific and Abcam are major players in the polyclonal antibodies market
TABLE 29 POLYCLONAL RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.2.3 Recombinant antibodies
6.3.2.3.1 Recombinant antibodies provide a highly specific & sensitive option for cancer treatment
TABLE 30 RECOMBINANT RESEARCH ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.3 ANTIBODIES, BY SOURCE
TABLE 31 ANTIBODIES, BY SOURCE
TABLE 32 RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
6.3.3.1 Mice
6.3.3.1.1 Mice are the preferred hosts for research-use antibody production
TABLE 33 MOUSE ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.3.2 Rabbits
6.3.3.2.1 Rabbits are a cost-effective means of antibody production
TABLE 34 RABBIT ANTIBODIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.3.3 Other sources
TABLE 35 OTHER ANTIBODY SOURCES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.4 ANTIBODIES, BY RESEARCH AREA
TABLE 36 ANTIBODIES, BY RESEARCH AREA
TABLE 37 RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
6.3.4.1 Oncology
6.3.4.1.1 High prevalence of cancer has boosted oncology research
TABLE 38 RESEARCH ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.4.2 Infectious diseases
6.3.4.2.1 Rising awareness and growing research activity are key drivers of the market
TABLE 39 RESEARCH ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.4.3 Immunology
6.3.4.3.1 Antibodies are used to identify protein and peptides to understand infectious disease immunology better
TABLE 40 RESEARCH ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.4.4 Neurobiology
6.3.4.4.1 Antibody-based approaches are widely used in molecular and cellular neuroscience
TABLE 41 RESEARCH ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.4.5 Stem cells
6.3.4.5.1 Increasing funding and the growing importance of stem cells in transplantation are key market drivers
TABLE 42 RESEARCH ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2020–2027 (USD MILLION)
6.3.4.6 Other research areas
TABLE 43 RESEARCH ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2020–2027 (USD MILLION)

7 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY (Page No. – 111)
7.1 INTRODUCTION
TABLE 44 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
7.2 WESTERN BLOTTING
7.2.1 HIGH ACCURACY, EASE OF INTERPRETATION, AND OTHER ADVANTAGES HAVE PROPELLED THE USE OF WESTERN BLOTTING
TABLE 45 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR WESTERN BLOTTING, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 FLOW CYTOMETRY
7.3.1 FLOW CYTOMETRY IS THE FASTEST-GROWING TECHNOLOGY SEGMENT OF THE MARKET
TABLE 46 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR FLOW CYTOMETRY, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 ENZYME-LINKED IMMUNOSORBENT ASSAY
7.4.1 ELISA HAS THE POTENTIAL TO SUPERSEDE THE CURRENT GOLD STANDARD FOR COVID-19 TESTING
TABLE 47 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ELISA, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 IMMUNOHISTOCHEMISTRY
7.5.1 COMPLEXITIES OF IHC POSE CHALLENGES TO MARKET GROWTH
TABLE 48 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2020–2027 (USD MILLION)
7.6 IMMUNOFLUORESCENCE
7.6.1 IMMUNOFLUORESCENCE HELPS DETERMINE SPECIFIC GENE EXPRESSIONS
TABLE 49 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOFLUORESCENCE, BY COUNTRY, 2020–2027 (USD MILLION)
7.7 IMMUNOPRECIPITATION
7.7.1 RESULTS OBTAINED BY IP CAN BE ANALYZED THROUGH OTHER TECHNOLOGIES
TABLE 50 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR IMMUNOPRECIPITATION, BY COUNTRY, 2020–2027 (USD MILLION)
7.8 OTHER TECHNOLOGIES
TABLE 51 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)

8 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION (Page No. – 123)
8.1 INTRODUCTION
TABLE 52 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 PROTEOMICS
8.2.1 PROTEOMICS HOLDS THE LARGEST SHARE OF THE MARKET, BY APPLICATION
TABLE 53 TECHNOLOGICAL APPLICATIONS OF ANTIBODIES IN PROTEOMICS
TABLE 54 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PROTEOMICS, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 DRUG DEVELOPMENT
8.3.1 THE DRUG DEVELOPMENT APPLICATIONS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST RATE
FIGURE 26 APPLICATION OF ANTIBODIES IN THE DRUG DEVELOPMENT PROCESS
TABLE 55 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 GENOMICS
8.4.1 GENOMICS IS AN EMERGING AREA OF RESEARCH APPLICATIONS EXPECTED TO SEE GROWTH IN THE COMING YEARS
TABLE 56 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR GENOMICS, BY COUNTRY, 2020–2027 (USD MILLION)

9 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER (Page No. – 130)
9.1 INTRODUCTION
TABLE 57 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 PHARMA & BIOTECH COMPANIES DOMINATE THE END-USER MARKET
TABLE 58 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 ACADEMIC & RESEARCH INSTITUTIONS
9.3.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL THE MARKET
TABLE 59 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 CONTRACT RESEARCH ORGANIZATIONS
9.4.1 GROWING CONTRACT RESEARCH ON MONOCLONAL ANTIBODIES AND DRUG CONJUGATES AIDS MARKET GROWTH
TABLE 60 RESEARCH ANTIBODIES AND REAGENTS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

10 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION (Page No. – 135)
10.1 INTRODUCTION
FIGURE 27 RESEARCH ANTIBODIES AND REAGENTS MARKET: GEOGRAPHIC SNAPSHOT (2021)
TABLE 61 RESEARCH ANTIBODIES AND REAGENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT
TABLE 62 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 64 NORTH AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 65 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 66 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 68 NORTH AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 69 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 70 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 71 NORTH AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 The US dominates the North American market in terms of market share
TABLE 72 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2019 VS. FY 2020 (USD BILLION)
TABLE 73 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 74 US: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 US: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 US: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 77 US: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 78 US: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 79 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 80 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 81 US: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Rising cancer incidence and a favorable funding scenario will push market growth in Canada
TABLE 82 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 83 CANADA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 CANADA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 CANADA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 86 CANADA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 87 CANADA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 88 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 89 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 90 CANADA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3 EUROPE
TABLE 91 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 93 EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 94 EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 95 EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 96 EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 97 EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 98 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 99 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 100 EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany holds the largest share of the market in Europe
TABLE 101 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 102 GERMANY: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 103 GERMANY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 104 GERMANY: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 105 GERMANY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 106 GERMANY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 107 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 108 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 109 GERMANY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.2 UK
10.3.2.1 The market in the UK is characterized by expansions by leading players and growing R&D investments
TABLE 110 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 111 UK: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 112 UK: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 113 UK: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 114 UK: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 115 UK: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 116 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 117 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 118 UK: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Rising infrastructural development and research activity support market growth in France
TABLE 119 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 120 FRANCE: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 121 FRANCE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 122 FRANCE: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 123 FRANCE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 124 FRANCE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 125 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 126 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 127 FRANCE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Increasing R&D in life sciences and favorable funding are key drivers of the Italian market
TABLE 128 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 129 ITALY: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 130 ITALY: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 131 ITALY: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 132 ITALY: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 133 ITALY: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 134 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 135 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 136 ITALY: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 A favorable scenario for research initiatives drives the market in Spain
TABLE 137 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 138 SPAIN: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 139 SPAIN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 140 SPAIN: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 141 SPAIN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 142 SPAIN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 143 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 144 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 145 SPAIN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 146 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 147 REST OF EUROPE: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 148 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 149 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 150 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 151 REST OF EUROPE: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 152 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 153 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 154 REST OF EUROPE: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET SNAPSHOT
TABLE 155 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 156 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 157 ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 158 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 159 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 160 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 161 ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 162 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 163 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 164 ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Japan dominates the Asia Pacific market
TABLE 165 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 166 JAPAN: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 167 JAPAN: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 168 JAPAN: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 169 JAPAN: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 170 JAPAN: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 171 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 172 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 173 JAPAN: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.2 CHINA
10.4.2.1 China is the fastest-growing segment of the overall market
TABLE 174 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 175 CHINA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 176 CHINA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 CHINA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 178 CHINA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 179 CHINA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 180 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 181 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 182 CHINA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Strong economic growth and rising demand for pharmaceuticals are key market drivers in India
TABLE 183 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 184 INDIA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 185 INDIA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 186 INDIA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 187 INDIA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 188 INDIA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 189 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 190 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 191 INDIA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 192 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 193 REST OF ASIA PACIFIC: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 194 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 195 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 196 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 197 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 198 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 199 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 200 REST OF ASIA PACIFIC: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 BRAZIL AND MEXICO TO GROW AT HIGH RATES IN THE LATAM MARKET
TABLE 201 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 202 LATIN AMERICA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 203 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 204 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 205 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 206 LATIN AMERICA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 207 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 208 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 209 LATIN AMERICA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.6 MIDDLE EAST AND AFRICA
10.6.1 MEA HOLDS THE SMALLEST SHARE OF THE MARKET BUT IS EXPECTED TO PROVIDE STRONG GROWTH OPPORTUNITIES
TABLE 210 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY PRODUCT, 2020–2027 (USD MILLION)
TABLE 211 MEA: RESEARCH REAGENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 212 MEA: RESEARCH ANTIBODIES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 213 MEA: RESEARCH ANTIBODIES MARKET, BY FORM, 2020–2027 (USD MILLION)
TABLE 214 MEA: RESEARCH ANTIBODIES MARKET, BY SOURCE, 2020–2027 (USD MILLION)
TABLE 215 MEA: RESEARCH ANTIBODIES MARKET, BY RESEARCH AREA, 2020–2027 (USD MILLION)
TABLE 216 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 217 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 218 MEA: RESEARCH ANTIBODIES AND REAGENTS MARKET, BY END USER, 2020–2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. – 202)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 30 KEY DEVELOPMENTS IN RESEARCH ANTIBODIES AND REAGENTS MARKET
11.3 RESEARCH ANTIBODIES MARKET SHARE ANALYSIS
FIGURE 31 GLOBAL RESEARCH ANTIBODIES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021
11.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
FIGURE 32 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN THE RESEARCH ANTIBODIES AND REAGENTS MARKET, 2019–2021
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 33 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION QUADRANT, 2021
11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 34 RESEARCH ANTIBODIES AND REAGENTS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2021
11.7 COMPANY FOOTPRINT ANALYSIS
11.7.1 COMPANY PRODUCT FOOTPRINT
TABLE 219 COMPANY PRODUCT FOOTPRINT: RESEARCH ANTIBODIES AND REAGENTS MARKET (2021)
11.7.2 COMPANY REGIONAL FOOTPRINT
TABLE 220 COMPANY REGIONAL FOOTPRINT: RESEARCH ANTIBODIES AND REAGENTS MARKET (2021)
11.8 COMPETITIVE SITUATION AND TRENDS
TABLE 221 PRODUCT LAUNCHES
TABLE 222 DEALS
TABLE 223 OTHER DEVELOPMENTS

12 COMPANY PROFILES (Page No. – 214)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1 MAJOR PLAYERS
12.1.1 ABCAM PLC.
TABLE 224 ABCAM PLC.: BUSINESS OVERVIEW
FIGURE 35 ABCAM PLC: COMPANY SNAPSHOT (2021)
12.1.2 CELL SIGNALING TECHNOLOGY, INC.
TABLE 225 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
12.1.3 THERMO FISHER SCIENTIFIC, INC.
TABLE 226 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
12.1.4 MERCK KGAA
TABLE 227 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2021)
12.1.5 BD
TABLE 228 BD: BUSINESS OVERVIEW
FIGURE 38 BD: COMPANY SNAPSHOT (2021)
12.1.6 BIO-RAD LABORATORIES, INC.
TABLE 229 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
12.1.7 F. HOFFMANN-LA ROCHE
TABLE 230 F. HOFFMANN-LA ROCHE: BUSINESS OVERVIEW
FIGURE 40 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2021)
12.1.8 AGILENT TECHNOLOGIES, INC.
TABLE 231 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 41 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2021)
12.1.9 DANAHER CORPORATION
TABLE 232 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
12.1.10 LONZA
TABLE 233 LONZA.: BUSINESS OVERVIEW
FIGURE 43 LONZA: COMPANY SNAPSHOT (2021)
12.1.11 GENSCRIPT
TABLE 234 GENSCRIPT: BUSINESS OVERVIEW
FIGURE 44 GENSCRIPT: COMPANY SNAPSHOT (2021)
12.1.12 PERKINELMER, INC.
TABLE 235 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 45 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
12.1.13 BIOLEGEND
TABLE 236 BIOLEGEND: BUSINESS OVERVIEW
12.1.14 ILLUMINA, INC.
TABLE 237 ILLUMINA, INC.: BUSINESS OVERVIEW
FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
TABLE 238 PRODUCT LAUNCHES
12.2 OTHER COMPANIES
12.2.1 IMMUNOPRECISE ANTIBODIES LTD
TABLE 239 IMMUNOPRECISE ANTIBODIES LTD: COMPANY OVERVIEW
12.2.2 FUJIREBIO DIAGNOSTICS AB
TABLE 240 FUJIREBIO DIAGNOSTICS AB: COMPANY OVERVIEW
12.2.3 ANALYTIK JENA AG
TABLE 241 ANALYTIK JENA AG: COMPANY OVERVIEW
12.2.4 OMEGA BIO-TEK
TABLE 242 OMEGA BIO-TEK: COMPANY OVERVIEW
12.2.5 DOVETAIL GENOMICS
TABLE 243 DOVETAIL GENOMICS: COMPANY OVERVIEW
12.2.6 ATLAS ANTIBODIES
TABLE 244 ATLAS ANTIBODIES: COMPANY OVERVIEW

*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. – 275)
13.1 INSIGHTS OF INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 AVAILABLE CUSTOMIZATIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com